Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + Nivolumab in R/R Hodgkin Lymphoma
NCT02572167Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Oct 2015
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin, nivolumab in Hodgkin lymphoma (HL), sponsored by Seagen Inc.. Started Oct 2015; status: completed.
02
Drugs
brentuximab vedotinnivolumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02572167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572167.